

SELECTED PHARMACEUTICALS IN LATE STAGE U.S. AND E.U. DEVELOPMENT OR REGISTRATION as of 10/17/17

Therapeutic Area	Product Name	Indication Sought	U.S. Development Stage	E.U. Development Stage	
Cardiovascular and Metabolism	XARELTO® (rivaroxaban)	Reduce the risk of major adverse cardiac events (MACE) in patients with Chronic Heart Failure and significant Coronary Artery Disease (2)	Phase III		
		Prevention of Symptomatic VTE and VTE-related death in high-risk, medically ill pts (2)	Phase III		
		Secondary prevention of stroke in patients who have experienced Embolic Stroke of undetermined source (ESUS) (2)	Discontinued		
		Reduce the risk of MACE in patients with coronary or Peripheral Artery Disease (2)	Phase III		
		VTE prophylaxis in ambulatory cancer patients receiving chemo at high-risk for VTE (2)	Phase III		
		Long-term Prevention of Recurrent Symptomatic VTE (2)	Filed 4/17		
	INVOKANA® (canagliflozin)	Infrainguinal revascular (2) Diabetic Nephropathy (2) Reduce the risk of death in type 2 diabetes with established, or risk for, cardiovascular disease. (CANVAS /CANVAS-R) (2)	Phase III Phase III Filed 9/17	Phase III Filed 10/17	
Immunology	TREMFYA® (guselkumab)	Moderate to Severe Plaque Psoriasis Psoriatic arthritis	Approved 7/17 Phase III	Positive CHMP Opinion 9/17 Phase III	
	SIMPONI ARIA® (golimumab)	Ankylosing spondylitis Psoriatic arthritis Juvenile Idiopathic Arthritis (JIA)	Filed 12/16 Filed 12/16 Phase III		
	sirukumab	Rheumatoid Arthritis	Withdrawn 10/17	Withdrawn 10/17	
	STELARA® (ustekinumab)	Adolescents Psoriasis Pediatric Psoriasis Ulcerative Colitis	Approved 10/17 Phase III Phase III	Approved 6/15 Phase III Phase III	
Infectious Diseases and Vaccines	SYM TUZA™ (darunavir/cobicistat/emtricitabine/tenofovir alafenamide)	Single tablet regimen for HIV in treatment naïve patients and treatment experienced patients (2)	Filed 9/17	Approved 9/17	
	EDURANT® STR (rilpivirine and dolutegravir)	Single tablet regimen for HIV in treatment experienced patients (2)	Filed 6/17	Filed 5/17	
	Rilpivirine Long Acting nanosuspension for injection	HIV Infection	Phase III	Phase III	
	cadazolid	Clostridium difficile-associated diarrhea (2)	Phase III	Phase III	
Neuroscience	esketamine	Treatment-resistant depression Major depressive disorder with imminent risk for suicide	Phase III Phase III	Phase III Phase III	
	ponesimod	Relapsing multiple sclerosis (2)	Phase III	Phase III	
Oncology	DARZALEX®	Frontline multiple myeloma transplant eligible in combination with bortezomib, thalidomide and dexamethasone (MMY 3006) (2)	Phase III	Phase III	
		Frontline multiple myeloma transplant ineligible patients in combination with bortezomib, melphalan, and prednisone (MMY 3007) (2)	Phase III	Phase III	
		Frontline multiple myeloma transplant ineligible patients in combination with lenalidomide and low dose dexamethasone (MMY 3008) (2)	Phase III	Phase III	
		Relapsed Refractory MM 1+ prior lines w/PomDex (2)	Phase III	Phase III	
	IMBRUVICA® (ibrutinib)	Treatment naïve patients with Mantle Cell Lymphoma in combination with Bendamustine and Rituximab (randomized study MCL-3002) (2)	Phase III	Phase III	
		Relapsed/refractory patients with Indolent Non-Hodgkins Lymphoma in combination with Bendamustine and Rituximab or R-CHOP; (randomized study FLR-3001) (2)	Phase III	Phase III	
		Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma in combination with R-CHOP (randomized study DBL3001) (2)	Phase III	Phase III	
		Previously Treated Adults with Waldenstrom's Macroglobulinemia with Rituximab (PCYC-1127) (2)	Phase III	Phase III	
		Frontline Chronic Lymphocytic Leukemia (Young and Fit) (in combination with Rituximab) (ECOG 1912) (2)	Phase III	Phase III	
		Chronic graft-versus-host-disease (cGVHD) after failure of one or more lines of systemic therapy (2)	Approved 8/17		
		Frontline Chronic Lymphocytic Leukemia in combination with obinutuzumab (PCYC-1130) (2)	Phase III	Phase III	
		Frontline Chronic graft-versus-host-disease (cGVHD) (2)	Phase III	Phase III	
	apalutamide (ARN-509)	Prostate cancer pre-metastatic castration-resistant Metastatic hormone sensitive prostate cancer Localized prostate cancer	Filed 10/17 Phase III Phase III	Phase III Phase III Phase III	
		apalutamide (ARN-509)/ ZYTIGA® (abiraterone acetate)	Prostate Cancer metastatic castration resistant chemotherapy naïve	Phase III	Phase III
		talacotuzumab (CSL362)	AML frontline not fit for chemo (2)	Discontinued	Discontinued
YONDELIS® (trabectedin)	Relapsed Ovarian Cancer (2)	Phase III			
ZYTIGA® (abiraterone acetate)	Prostate Cancer Newly Diagnosed Hormone Naïve Metastatic	Filed 9/17	Positive CHMP Opinion 10/17		

* This information is accurate as of the date hereof to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information.

(2) INVOKANA licensed from Mitsubishi Tanabe Pharma Corporation; SYMTUZA developed in collaboration with Gilead Sciences; EDURANT STR developed in collaboration with ViiV Healthcare; YONDELIS developed in collaboration with PharmaMar S.A.; XARELTO co-developed with Bayer HealthCare; INVEGA SUSTENNA includes technology licensed from Alkermes, Inc.; DARZALEX licensed from Genmab A/S; IMBRUVICA developed in collaboration with Pharmacyclics, LLC, an AbbVie company; Talacotuzumab licensed from CSL Limited Ponesimod and Cadazolid developed by Actelion, a Janssen Pharmaceutical Company of Johnson & Johnson

Janssen Pharmaceutical Companies of Johnson & Johnson
Selected NME Pharmaceutical Pipeline - Recent Approvals/Potential Filings*
 Selective Highlights as of October 17, 2017

NMEs APPROVED 2016/2017	NMEs IN REGISTRATION	NME PLANNED FILINGS 2017-2021*	
Oncology	Oncology	Oncology	Neuroscience
DARZALEX® (daratumumab) Double Refractory multiple myeloma	Apalutamide (ARN-509) Pre-metastatic prostate cancer	Imetelstat Myelofibrosis	Esketamine Treatment resistant depression
Immunology		Erdafitinib (FGFRI kinase inhibitor) Urothelial cancer	Seltorexant (JNJ-7922) Adjunctive treatment for major depressive disorder
TREMFYA® (guselkumab) Psoriasis		Niraparib Metastatic castration-resistant prostate cancer (mCRPC)	Ponesimod Relapsing multiple sclerosis
			Infectious Diseases & Vaccines
			Lumicitabine (JNJ-1575) RSV infection
			VAC18193 (RSV vaccine) RSV elderly
			JNJ-1860 (ExPEC vaccine) Bacterial infection
			Pimodivir (JNJ-3872) Influenza A

*Filings/approvals assumed to be in the US and EU unless otherwise noted. This information is accurate as of the date hereof to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information. DARZALEX licensed from Genmab A/S; Seltorexant (Orexin -2) antagonist codeveloped with Minerva Neurosciences; Imetelstat licensed from Geron; Pimodivir (JNJ-3872) licensed from Vertex Pharmaceuticals, Inc.; Niraparib licensed from Tesaro; Talacotuzumab licensed from CSL Limited; Erdafitinib discovered in collaboration with Astex Pharmaceuticals, Inc.; Ponesimod developed by Actelion, a Janssen Pharmaceutical Company of Johnson & Johnson

